Talk:Catumaxomab
Latest comment: 4 years ago by 69.203.73.17 in topic Fatality in a clinical trial should be mentioned
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Catumaxomab.
|
 | This article contains a translation of Catumaxomab from de.wikipedia. (326739962 et seq.) |
T-lymphocytes edit
Catumaxomab works by linking the T-lymphocytes with the cancer cells. --Blake3522 08:24, 14 July 2007 (UTC)
- Yes. --Blake3522 10:33, 27 July 2007 (UTC)
No mention of Bispecific edit
Just thought I'd leave a note to say there's no mention of bispecific on this page and its somewhat significant as being the first approved (see bispecific wiki page and also https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784585/). If anyone wants to add it, that'd be great, I'll add it at some point in the future if not (bit busy currently). --TobyBrann 16:02, 13 August 2019 (UTC)
Fatality in a clinical trial should be mentioned edit
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/pdf/oncotarget-07-28059.pdf — Preceding unsigned comment added by 69.203.73.17 (talk) 03:03, 1 April 2020 (UTC)